Maxim Group Has Lowered Expectations for Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price

Reviva Pharmaceuticals (NASDAQ:RVPH) had its price target reduced by Maxim Group from $5.00 to $2.00 in a research report report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts have also weighed in on RVPH. Citigroup reaffirmed a “buy” rating on shares of Reviva Pharmaceuticals in a research report on Friday. D. Boral Capital reaffirmed a “buy” rating and set a $3.00 price objective on shares of Reviva Pharmaceuticals in a research report on Friday, June 27th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Reviva Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $8.00.

Reviva Pharmaceuticals Price Performance

NASDAQ RVPH opened at $0.54 on Friday. The firm has a market capitalization of $25.92 million, a price-to-earnings ratio of -0.83 and a beta of -0.05. The company has a 50 day simple moving average of $0.51 and a 200-day simple moving average of $0.89. Reviva Pharmaceuticals has a 52-week low of $0.30 and a 52-week high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. On average, analysts predict that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Ameriprise Financial Inc. acquired a new stake in Reviva Pharmaceuticals in the 4th quarter valued at approximately $84,000. Tower Research Capital LLC TRC boosted its position in shares of Reviva Pharmaceuticals by 848.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after acquiring an additional 23,953 shares during the period. Geode Capital Management LLC grew its stake in shares of Reviva Pharmaceuticals by 11.9% in the fourth quarter. Geode Capital Management LLC now owns 311,701 shares of the company’s stock worth $564,000 after acquiring an additional 33,205 shares during the last quarter. Cornerstone Select Advisors LLC acquired a new stake in shares of Reviva Pharmaceuticals in the fourth quarter worth $32,000. Finally, BluePointe Capital Management LLC increased its position in Reviva Pharmaceuticals by 354.7% during the first quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock worth $45,000 after acquiring an additional 36,807 shares during the period. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.